Nature Medicine, Published online: 28 February 2026; doi:10.1038/s41591-026-04263-3 Results from a phase 1 trial of a first-in-class small-molecule inverse agonist of PPARγ in solid tumors show an acceptable safety profile and preliminary tumor activity in urothelial carcinoma.
Nature Medicine, Published online: 28 February 2026;
doi:10.1038/s41591-026-04263-3
Results from a phase 1 trial of a first-in-class small-molecule inverse agonist of PPARγ in solid tumors show an acceptable safety profile and preliminary tumor activity in urothelial carcinoma.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04263-3)